Robert Aiken
Distinguished in Meningioma

Dr. Robert Aiken

Neurology
Atlantic Health
Gerald J. Glasser Brain Tumor Center
99 Beauvoir Avenue, Floor 5, 
Summit, NJ 
On Staff At
Accepting New Patients
Offers Telehealth

Distinguished in Meningioma
Atlantic Health
Gerald J. Glasser Brain Tumor Center
99 Beauvoir Avenue, Floor 5, 
Summit, NJ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Dr. Robert Aiken is a fellowship-trained neuro-oncologist and part of the Atlantic Medical Group Neuroscience Institute at Overlook Medical Center. With years of expertise in academic, clinical and administrative roles, and board-certified in neurology and neuro-oncology, he specializes in the diagnosis and management of patients with brain tumors, tumors of the spinal cord and nerves, as well as the management of paraneoplastic disorders involving the brain and nervous system. His particular interest involves translating new discoveries and developing new therapies for these disorders. A devoted researcher and educator, Dr. Aiken serves as co-director of the Gerald J. Glasser Brain Tumor Center at Atlantic Health System. He also served as director of neuro-oncology at Rutgers-Cancer Institute of New Jersey of Rutgers University. Previously, he held academic appointments in neurology, neurosurgery and oncology at Mount Sinai School of Medicine in NYC and Rush University Medical Center in Chicago. He combines clinical knowledge and extensive research in brain and spinal tumors. Dr. Aiken provides patients with a comprehensive evaluation and discusses their disease at length and the available treatments. After receiving his medical degree from Wayne State University School of Medicine in Detroit, MI, Dr. Aiken completed an internship and residency in internal medicine at Baylor College of Medicine in Houston, TX, then pursued neurologic training at the Neurological Institute of New York, Columbia-Presbyterian Medical Center. Post-residency, Dr. Aiken received his fellowship training at Memorial Sloan-Kettering Cancer Center. He is the author of many professional research journal articles. Dr. Aiken has been named among America’s Top Doctors and America’s Top Doctors for Cancer from Castle Connolly, Best Doctors in Philadelphia, New York and Chicago and by Inside Jersey magazine. He is on many best doctors lists. Dr. Aiken is part of Atlantic Medical Group and a participating provider of the Atlantic Accountable Care Organization.

Dr. Aiken is rated as a Distinguished provider by MediFind in the treatment of Meningioma. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, and Gliosarcoma.

His clinical research consists of co-authoring 19 peer reviewed articles and participating in 18 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Wayne State University
Residency
Baylor College of Medicine
Specialties
Neurology
Licenses
Psychiatry & Neurology in NJ
Board Certifications
American Board Of Psychiatry And Neurology
Fellowships
Memorial Sloan Kettering Cancer Center
Hospital Affiliations
Morristown Medical Center
Atlantic Medical Group
Overlook Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Ambetter
  • EPO
  • HMO
  • PPO
AmeriHealth
  • EPO
  • HMO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Longevity Health Plan
  • MEDICARE SNP
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

Gerald J. Glasser Brain Tumor Center
99 Beauvoir Avenue, Floor 5, Summit, NJ 07901
Call: 908-522-5914
Other Locations
Gerald J. Glasser Brain Tumor Center
100 Madison Avenue, Carol G. Simon Cancer Center Null, Morristown, NJ 07960
Gerald J. Glasser Brain Tumor Center
11 Overlook Road, MAC II, Suite 180 Null, Summit, NJ 07901
Gerald J. Glasser Brain Tumor Center
901 West Main Street, Statesir Cancer Center Null, Freehold, NJ 07728
Call: 908-522-5914

Additional Areas of Focus

Dr. Aiken has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


18 Clinical Trials

A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors
A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Drug, Procedure
Study Drug: Olaparib
Study Phase: Phase 2
Genomically-Guided Treatment Trial in Brain Metastases
Genomically-Guided Treatment Trial in Brain Metastases
Enrollment Status: Suspended
Publish Date: February 04, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Paxalisib, Entrectinib
Study Phase: Phase 2
An Open-Label, Multi-Center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With REGN2810 in Subjects With Newly-Diagnosed Glioblastoma (GBM)
An Open-Label, Multi-Center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With REGN2810 in Subjects With Newly-Diagnosed Glioblastoma (GBM)
Enrollment Status: Active_not_recruiting
Publish Date: January 28, 2026
Intervention Type: Biological, Drug, Radiation
Study Drugs: INO-5401, INO-9012, Cemiplimab, Temozolomide
Study Phase: Phase 1/Phase 2
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: December 18, 2025
Intervention Type: Other, Biological, Procedure, Drug, Radiation, Device
Study Drugs: Ipilimumab, Nivolumab, Temozolomide
Study Phase: Phase 2/Phase 3
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Enrollment Status: Active_not_recruiting
Publish Date: November 28, 2025
Intervention Type: Other, Drug
Study Drugs: Temozolomide, Veliparib
Study Phase: Phase 2/Phase 3
A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma
A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma
Enrollment Status: Active_not_recruiting
Publish Date: September 09, 2025
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas
Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas
Enrollment Status: Approved_for_marketing
Publish Date: August 20, 2025
Intervention Type: Drug
A Randomized Phase 2 Trial of Cediranib and Olaparib Compared to Bevacizumab in Patients With Recurrent Glioblastoma Who Have Not Received Prior VEGF Therapy
A Randomized Phase 2 Trial of Cediranib and Olaparib Compared to Bevacizumab in Patients With Recurrent Glioblastoma Who Have Not Received Prior VEGF Therapy
Enrollment Status: Active_not_recruiting
Publish Date: August 03, 2025
Intervention Type: Drug, Biological
Study Drugs: Bevacizumab, Cediranib, Cediranib Maleate, Olaparib
Study Phase: Phase 2
A Multicenter, Open-Label Study With a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy
A Multicenter, Open-Label Study With a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy
Enrollment Status: Active_not_recruiting
Publish Date: May 04, 2025
Intervention Type: Drug
Study Drugs: Berubicin, Lomustine
Study Phase: Phase 2
A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, ALLIANCE IND # 15380) Vaccine Given With Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, ALLIANCE IND # 15380) Vaccine Given With Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
Enrollment Status: Terminated
Publish Date: January 24, 2025
Intervention Type: Biological, Drug
Study Drugs: HSPPC-96, Bevacizumab
Study Phase: Phase 2
A Phase 1/2 Study of Selinexor in Combination With Standard of Care (SoC) Therapy for Newly Diagnosed or Recurrent Glioblastoma
A Phase 1/2 Study of Selinexor in Combination With Standard of Care (SoC) Therapy for Newly Diagnosed or Recurrent Glioblastoma
Enrollment Status: Terminated
Publish Date: December 16, 2024
Intervention Type: Drug, Device, Radiation
Study Drugs: Selinexor, Temozolomide (TMZ), Lomustine (CCNU), Bevacizumab, Carmustine
Study Phase: Phase 1/Phase 2
Prospective Randomized Placebo-Controlled Trial of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)
Prospective Randomized Placebo-Controlled Trial of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)
Enrollment Status: Active_not_recruiting
Publish Date: February 26, 2024
Intervention Type: Biological
Study Drug: SurVaxM
Study Phase: Phase 2
Phase I/II Clinical Trial of the Safety, Tolerability, and Anti-tumor Efficacy of the IGF-1R Inhibitor, AXL1717 (Picropodophyllin), in the Treatment of Recurrent Malignant Astrocytomas
Phase I/II Clinical Trial of the Safety, Tolerability, and Anti-tumor Efficacy of the IGF-1R Inhibitor, AXL1717 (Picropodophyllin), in the Treatment of Recurrent Malignant Astrocytomas
Enrollment Status: Terminated
Publish Date: May 22, 2023
Intervention Type: Drug
Study Drug: AXL1717
Study Phase: Phase 1/Phase 2
A Randomized, Placebo Controlled Phase 3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)
A Randomized, Placebo Controlled Phase 3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)
Enrollment Status: Completed
Publish Date: May 11, 2023
Intervention Type: Drug, Radiation
Study Drugs: Temozolomide, Depatuxizumab
Study Phase: Phase 3
G-FORCE-1: An Open-Label Phase 1 Two Part Dose Escalation Trial of RRx-001 Concurrent With Radiation and Temozolomide and RRx-001 + Temozolomide Post-RT In Newly Diagnosed Glioblastoma and Anaplastic Gliomas With Intact 1p/19q Chromosomes
G-FORCE-1: An Open-Label Phase 1 Two Part Dose Escalation Trial of RRx-001 Concurrent With Radiation and Temozolomide and RRx-001 + Temozolomide Post-RT In Newly Diagnosed Glioblastoma and Anaplastic Gliomas With Intact 1p/19q Chromosomes
Enrollment Status: Completed
Publish Date: May 16, 2022
Intervention Type: Drug, Radiation
Study Drugs: RRx-001+TMZ+RT, Temozolomide
Study Phase: Phase 1
Phase II Trial of Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens (AV-GBM-1) as an Adjunctive Therapy Following Primary Surgery Plus Concurrent Chemoradiation in Patients With Newly Diagnosed Glioblastoma
Phase II Trial of Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens (AV-GBM-1) as an Adjunctive Therapy Following Primary Surgery Plus Concurrent Chemoradiation in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Unknown
Publish Date: December 16, 2021
Intervention Type: Biological
Study Drug: AV-GBM-1
Study Phase: Phase 2
A Phase 1 Dose-Escalation Study of RRx-001 in Combination With Whole Brain Radiation in Subjects With Brain Metastases (BRAINSTORM)
A Phase 1 Dose-Escalation Study of RRx-001 in Combination With Whole Brain Radiation in Subjects With Brain Metastases (BRAINSTORM)
Enrollment Status: Completed
Publish Date: November 03, 2021
Intervention Type: Drug
Study Drug: RRx-001
Study Phase: Phase 1
A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)
A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)
Enrollment Status: Completed
Publish Date: July 15, 2021
Intervention Type: Biological
Study Drugs: DNX-2401 Adeno-Associated Oncolytic Virus Delta-24 Vaccine, Pembrolizumab
Study Phase: Phase 2
View 17 Less Clinical Trials

19 Total Publications

Phase 2 trial of personal dendritic cell vaccines in newly diagnosed glioblastoma: 3-year follow-up and correlations with survival.
Phase 2 trial of personal dendritic cell vaccines in newly diagnosed glioblastoma: 3-year follow-up and correlations with survival.
Journal: Human vaccines & immunotherapeutics
Published: September 12, 2025
View All 19 Publications
Similar Doctors
Elite in Meningioma
Dr. Thomas J. Kaley
Neurology
Elite in Meningioma
Dr. Thomas J. Kaley
Neurology

Memorial Neurology Group

1275 York Ave, 
New York, NY 
 (21.1 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Thomas Kaley is a Neurologist in New York, New York. Dr. Kaley is rated as an Elite provider by MediFind in the treatment of Meningioma. His top areas of expertise are Astrocytoma, Meningioma, Glioblastoma, and Glioma.

Susan C. Pannullo
Elite in Meningioma
Dr. Susan C. Pannullo
Neurosurgery | Neurology
Elite in Meningioma
Dr. Susan C. Pannullo
Neurosurgery | Neurology

Weill Cornell Medicine

525 East 68th Street, Suite 99, 
New York, NY 
 (21.2 miles away)
212-746-2438
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Susan Pannullo is a Neurologist and a Neurosurgery provider in New York, New York. Dr. Pannullo is rated as a Distinguished provider by MediFind in the treatment of Meningioma. Her top areas of expertise are Meningioma, Acoustic Neuroma, Metastatic Brain Tumor, and Brain Tumor. Dr. Pannullo is currently accepting new patients.

Elite in Meningioma
Dr. Rajiv S. Magge
Neurology
Elite in Meningioma
Dr. Rajiv S. Magge
Neurology

Weill Medical College Of Cornell

1305 York Ave, 
New York, NY 
 (21.2 miles away)
646-962-9800
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Rajiv Magge is a Neurologist in New York, New York. Dr. Magge has been practicing medicine for over 17 years and is rated as a Distinguished provider by MediFind in the treatment of Meningioma. His top areas of expertise are Meningioma, Astrocytoma, Glioblastoma, and Brain Tumor.

VIEW MORE MENINGIOMA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Aiken's expertise for a condition
ConditionClose
  • Elite
  • Astrocytoma
    Dr. Aiken is
    Elite
    . Learn about Astrocytoma.
    See more Astrocytoma experts
  • Glioblastoma
    Dr. Aiken is
    Elite
    . Learn about Glioblastoma.
    See more Glioblastoma experts
  • Glioma
    Dr. Aiken is
    Elite
    . Learn about Glioma.
    See more Glioma experts
  • Distinguished
  • Atypical Teratoid Rhabdoid Tumor (ATRT)
    Dr. Aiken is
    Distinguished
    . Learn about Atypical Teratoid Rhabdoid Tumor (ATRT).
    See more Atypical Teratoid Rhabdoid Tumor (ATRT) experts
  • Brain Tumor
    Dr. Aiken is
    Distinguished
    . Learn about Brain Tumor.
    See more Brain Tumor experts
  • Embryonal Tumor with Multilayered Rosettes
    Dr. Aiken is
    Distinguished
    . Learn about Embryonal Tumor with Multilayered Rosettes.
    See more Embryonal Tumor with Multilayered Rosettes experts
  • Gliomatosis Cerebri
    Dr. Aiken is
    Distinguished
    . Learn about Gliomatosis Cerebri.
    See more Gliomatosis Cerebri experts
  • Gliosarcoma
    Dr. Aiken is
    Distinguished
    . Learn about Gliosarcoma.
    See more Gliosarcoma experts
  • Meningioma
    Dr. Aiken is
    Distinguished
    . Learn about Meningioma.
    See more Meningioma experts
View All 8 Distinguished Conditions
  • Advanced
  • Ependymoma
    Dr. Aiken is
    Advanced
    . Learn about Ependymoma.
    See more Ependymoma experts
  • Metastatic Brain Tumor
    Dr. Aiken is
    Advanced
    . Learn about Metastatic Brain Tumor.
    See more Metastatic Brain Tumor experts
  • Pediatric Low-Grade Glioma (pLGG)
    Dr. Aiken is
    Advanced
    . Learn about Pediatric Low-Grade Glioma (pLGG).
    See more Pediatric Low-Grade Glioma (pLGG) experts
  • Posterior Fossa Tumor
    Dr. Aiken is
    Advanced
    . Learn about Posterior Fossa Tumor.
    See more Posterior Fossa Tumor experts
  • Primitive Neuroectodermal Tumor (PNET)
    Dr. Aiken is
    Advanced
    . Learn about Primitive Neuroectodermal Tumor (PNET).
    See more Primitive Neuroectodermal Tumor (PNET) experts
  • Experienced
  • Brain Stem Cancer
    Dr. Aiken is
    Experienced
    . Learn about Brain Stem Cancer.
    See more Brain Stem Cancer experts
  • Choroid Plexus Papilloma
    Dr. Aiken is
    Experienced
    . Learn about Choroid Plexus Papilloma.
    See more Choroid Plexus Papilloma experts
  • Diencephalic Syndrome
    Dr. Aiken is
    Experienced
    . Learn about Diencephalic Syndrome.
    See more Diencephalic Syndrome experts
  • Diffuse Midline Glioma H3 K27M-Mutant
    Dr. Aiken is
    Experienced
    . Learn about Diffuse Midline Glioma H3 K27M-Mutant.
    See more Diffuse Midline Glioma H3 K27M-Mutant experts
  • Dysembryoplastic Neuroepithelial Tumors (DNET)
    Dr. Aiken is
    Experienced
    . Learn about Dysembryoplastic Neuroepithelial Tumors (DNET).
    See more Dysembryoplastic Neuroepithelial Tumors (DNET) experts
  • Neural Crest Tumor
    Dr. Aiken is
    Experienced
    . Learn about Neural Crest Tumor.
    See more Neural Crest Tumor experts
View All 8 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.